Repligen: Acquisition To Add Cell Therapy Capabilities (NASDAQ:RGEN)
· seekingalpha.com
Repligen’s $1.5B BioLife acquisition and strong Q2 results lift guidance, but valuation looks stretched. Click for more on RGEN stock.
If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major e...